The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Open accessAbstract
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n = 616) or placebo (Z3P3, n = 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference = 1.04%; 95% confidence interval 0.4 to 1.7; p = 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n = 14) versus Z3P3 (n = 30) group (odds ratio = 0.51; p = 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p = 0.26) and stroke (3.1% versus 1.5% in Z3P3; p = 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327). © 2012 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation after 18+ years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476908 · Cited by 4,072
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationMultiple Imputation After 18+ Years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.2307/2291635 · Cited by 2,686
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,876
Flagged first, then by citations
Research works printed but not linked: 2
- Black, 2004, A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX), J Bone Miner Res., 19
- Cosman, 2011, After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment?, J Bone Miner Res., 26
Cited by
Sorted by citations
Items 601–699 of 699
Roux, C., & Briot, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_16
Jaszczyk, B., & Wisłowska, M. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.5206
Injectable High Viscosity Liquid Carriers for Bone Tissue Engineering
Cheng, T. L. (2016) · The Sydney eScholarship Repository (The University of Sydney)
The Impact of Regulatory and Scientific Organizations’ Recommendations on Clinical Decision-Making
Παπαϊωάννου, Α., Agarwal, A., & Karampatos, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_21
Long-Term Efficacy and Safety of Treatments for Osteoporosis
Papapoulos, S. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_15
Controversias en el tratamiento de la osteoporosis posmenopáusica
Sotelo, W., & Vásquez, E. A. (2016) · Revista Peruana de Ginecología y Obstetricia · doi:10.31403/rpgo.v62i1910
Hamdy, R. C. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316084380.045
(2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316084380.035
Evolve osteoporosis and other guidelines avoiding cognitive bias
O'Donnell, J. L. (2016) · Internal Medicine Journal · doi:10.1111/imj.13212
Metcalf, T., & March, L. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.087
Est-il temps de passer au treat to target dans l’ostéoporose ?
Chapurlat, R. D. (2017) · Revue du Rhumatisme · doi:10.1016/j.rhum.2016.12.011
Women’s health 2016: An update for internists
Batur, P., Schwarz, E. B., Walsh, J. M. E., & Johnson, K. M. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.16098
Labordiagnostik bei metabolischen Knochenerkrankungen – Möglichkeiten und Grenzen
Lange, U., & Reuss-Borst, M. A. (2017) · Aktuelle Rheumatologie · doi:10.1055/s-0042-114978
Les bisphosphonates dans le traitement de l’ostéoporose
Brown, J. P., Morin, S. N., Leslie, W. D., Παπαϊωάννου, Α., Cheung, A. M., Davison, K. S., Goltzman, D., Hanley, D. A., Hodsman, A. B., Josse, R. G., et al. (2014) · Canadian Family Physician
Osteoporose – Langzeitmanagement einer chronischen Erkrankung
Wildpaner, D., Pavese, C., & Weber, M. (2017) · Praxis · doi:10.1024/1661-8157/a002651
Anagnostis, P. G., Paschou, S. Α., Mintziori, G., Ceauşu, I., Depypere, H. T., Lambrinoudaki, I. V., Mueck, A. O., Pérez-López, F. R., Rees, M., Senturk, L. M., et al. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.019
The Role of Osteocyte Apoptosis on Osteoclast Precursor Recruitment
Cheung, W.-Y. (2013) · TSpace (University of Toronto)
Medical management of bone loss from a spinal surgeon’s perspective
Truumees, E. (2017) · Seminars in Spine Surgery · doi:10.1053/j.semss.2017.09.012
Hinshaw, W. B., & Schneider, J. P. (2017) · International Journal of Medical and Pharmaceutical Case Reports · doi:10.9734/ijmpcr/2017/36791
Botresorptieremmers en preventie van osteonecrose van de kaak
WYNGAERT, T. V. D., & Lenssen, O. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-1784-4_12
Fracturas atípicas de fémur proximal asociadas al uso prolongado de bifosfonatos.
Neder, Y., Fazio, A., Valle, P. E., Faule, F., & Finola, M. (2018) · Revista de la Asociación Argentina de Ortopedia y Traumatología · doi:10.15417/issn.1852-7434.2018.83.3.748
Pharmacological Therapy: Past, Present, and Future
Migliaccio, S., Lenzi, A., & Greco, E. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-75110-8_17
Management of Patients with Increased Fracture Risk
Cosman, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-26757-9_6
Self-citationDispelling confusion about de‐prescribing bisphosphonates
Eisman, J. A., & White, C. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12058
Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate
Wilson, S., Sharp, C. A., & Davie, M. W. J. (2018) · Journal of Bone Biology and Osteoporosis · doi:10.18314/jbo.v4i1.1264
David, S. M., Chan, K., Inderjeeth, C. A., & Raymond, W. D. (2019) · Australian Journal on Ageing · doi:10.1111/ajag.12614
Die DVO Osteoporose Leitlinie: eine Analyse der Evidenzlage zu Bisphosphonaten
Thaler, K. J., Biber, N., & Glechner, A. (2019) · Osteologie/Osteology · doi:10.1055/a-0800-0882
Denosumab – die reversible Wirksamkeit im klinischen Fokus
Popp, A. W. (2019) · Osteologie/Osteology · doi:10.1055/a-0800-0815
Langzeitsicherheit von Bisphosphonaten
Gasser, R. W. (2019) · Osteologie/Osteology · doi:10.1055/a-0832-2837
Is it necessary to modify the clinical trials about osteoporosis? The serious problem of denosumab
Henríquez, M. S., Romero, M. J. G. D. T., & Suau, Ó. T. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.05.033
Osteoporose: Dauertherapie versus Therapiepause – Wofür gibt es Evidenz?
Farahmand, P., & Cassens, J. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00719-9
Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture
Hant, F. N., & Bolster, M. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_4
Veazie, S., Gilbert, J., Winchell, K. A., Paynter, R. A., & Guise, J. (2019)
Quando sospendere la terapia con bisfosfonati nel trattamento dell’osteoporosi
Biamonte, F., & Minisola, S. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00727-x
Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
Kurth, A. A. (2021) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-62426-5_51
Kurth, A. A., Rauschmann, M., & Hadji, P. (2020) · Die Wirbelsäule · doi:10.1055/a-0968-7097
¿Es necesario modificar los ensayos clínicos sobre osteoporosis? El grave problema de denosumab
Henríquez, M. S., Romero, M. J. G. D. T., & Suau, Ó. T. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.05.040
Long-term bisphosphonate treatment: continuation and interruption
Adler, R. A., Assaad, M. A., & Fuleihan, G. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00079-4
Marchenkova, L. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-134-141
Sospensione dei bisfosfonati e persistenza degli effetti terapeutici
Bellone, F., Morabito, N., Corica, F., & Catalano, A. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00892-7
Zoledronic Acid Induces Early Changes of VEGF Levels in Women With Postmenopausal OsteoporosisPreprint
Bellone, F., Catalano, A., Sottile, A. R., Gaudio, A., Loddo, S., Corica, F., & Morabito, N. (2021) · Research Square · doi:10.21203/rs.3.rs-530052/v1
Osteoporosis: A silent disease fraught with fragility fractures in geriatric population
Vashisht, A. (2021) · Annals of Geriatric Education and Medical Sciences · doi:10.18231/j.agems.2021.004
Clynes, M. A., & Dennison, E. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78128-6_5
Alvos terapêuticos em osteoporose
Domiciano, D. S. (2019) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2019.18.2.15-20
“Drug Holidays”: When and How?
Majety, P., & Malabanan, A. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_15
Effects of Osteoporosis Drugs: Morphological Assessment and Adverse Events
Kimmel, D. B. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_21
Bone Remodeling and Modeling: Therapeutic Targets for the Treatment of Osteoporosis
Langdahl, B. L. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_8
Verschiedene Perspektiven von Therapiepausen und Kombinations-therapien bei Osteoporose
Oser, S., & Häuselmann, H. J. (2021) · Praxis · doi:10.1024/1661-8157/a003762
Osteoporosis Management: Gaps in Patients’ Care and Treatment
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_21
Panneerselvam, N., Alamoudi, A., Riley, J. L., & Katz, J. (2022) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.59503
Pharmacological Treatment of Patients with Osteoporosis
Rizzoli, R. (2022) · Springer eBooks · doi:10.1007/978-3-030-91483-7_12
Managing Long-Term Bisphosphonate Use
(2016) · Lippincottʼs Bone and Joint Newsletter · doi:10.1097/01.bonej.0000482978.21575.bf
Osteoporose – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
Kurth, A. A. (2020) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-55793-8_51-1
Longer-term osteoporosis treatment may be advantageous
(2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.83
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-22102-6.00005-6
Mazanec, D. J., Khalaf, T. M., & Orr, R. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40030-5.00103-9
Directive clinique no 422g : Ménopause et ostéoporose
Khan, A. A., Alrob, H. A., Ali, D. S., Dandurand, K., Wolfman, W., & Fortier, M. P. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.03.004
Fracture Risk Assessment and Drug Holiday in a Real-Life Setting
Morkos, M., Baim, S., Go, M. T., Mahrous, P., Casagrande, A., Husni, H., Hanna, M., Bedrose, S. S. D., & Li, D. (2022) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2022.10.005
Le traitement à la cible (treat-to-target) dans l'ostéoporose
Bouvard, B., Hoppé, E., & Legrand, É. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-77859-9.00012-8
Osteoporosis Prevention and Treatment
Humphrey, M. B., Zahedi, B., Warriner, A. H., Morgan, S., Leder, B. Z., Saag, K. G., & Yu, E. W.-Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_41
Marchenkova, L. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-154
Bisphosphonates: Clinical Applications and Perspectives in Osteoporosis Treatment
Lim, S. Y., & Bolster, M. B. (2023) · Tissue repair and reconstruction · doi:10.1007/978-981-99-5826-9_1
İlaçlara Bağlı Gelişen Çene Kemiği Osteonekrozlarının Yönetiminde Güncel Değişimler
Şahi̇n, O., & Hacılar, M. (2023) · ADO Klinik Bilimler Dergisi · doi:10.54617/adoklinikbilimler.1313173
Antiresorptive Drugs’ Role in Management of Postmenopausal Osteoporosis
Marcucci, G. (2023) · Endocrinology · doi:10.1007/978-3-030-19632-5_13-1
Optimising zoledronate treatment holiday duration without loss of fracture prevention
Drake, M. T. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00064-0
Oral bisphosphonates—Initiating and maintaining treatment
Hamdy, R. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99550-4.00018-6
Zoledronic acid—Annual infusions
Hamdy, R. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99550-4.00011-3
Drug holiday effect on osteoporosis: a narrative review of the current literature
Velitsikakis, P.-A., Psochias, P., Kopanos, S., Perisynakis, N., & Giovanidis, G. (2024) · The Egyptian Orthopaedic Journal · doi:10.4103/eoj.eoj_141_23
Zikán, V. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.028
Frailty and Orthogeriatrics: Enhancing Care for Fragility Fractures
Vazquez-Guajardo, M., & Duque, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-57361-3_44
Jallali, T., Reiser, E., & Tóth, B. (2024) · Gynäkologie in der Praxis · doi:10.1007/s41974-024-00343-9
Medication-Related Osteonecrosis of the Jaw: MRONJ
Dholam, K. P., Gurav, S. V., & Singh, G. P. (2024) · Springer eBooks · doi:10.1007/978-981-99-5195-6_13
Postmenopausale Osteoporose und Osteoporose des Mannes über 50 Jahre
Rintelen, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-69693-4_21
The Role of Bisphosphonate Drug Holidays in the Management of Osteoporosis
Kim, S. S. Y., & Lau, A. C. K. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2331
Treatment Goals for Prevention of Vertebral Fractures in Patients with Rheumatoid Arthritis
Mochizuki, T., Ando, M., Yano, K., Hiroshima, R., Ikari, K., & Okazaki, K. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.24.811
Medical Management of Osteoporosis: Updates and Future Directions
Maldar, A. N., & Chadha, M. D. (2025) · Indian Spine Journal · doi:10.4103/isj.isj_87_24
Management of Osteoporosis in the Orthopedic Trauma Patient
Chou, S. H.-H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80825-8_8
Hong, S. H., Yu, Y. J., & Han, S.-B. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01560-1
Ko, S.-Y., Lin, J.-F., Lin, C.-H., & Cheng, Y.-Y. (2025) · Journal of Stroke & Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108456
Scharla, S. H. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00009-0
Horikawa, A., Kasukawa, Y., Hongo, M., Sano, A., & Miyakoshi, N. (2025) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2025.101642
Osteoporosis Drugs: Old and New Drugs
Federica, B., & Radaelli, M. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_8
Khatri, K., Gupta, N., Aggarwal, S., Lakhani, A., Dahuja, A., Kankaria, A., & Kanwal, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00017-5
Henriksen, B. T., Krogseth, M., Andersen, R. D., Davies, M. N., Nguyen, C. T., Mathiesen, L., & Andersson, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26597003
Henriksen, B. T., Krogseth, M., Andersen, R. D., Davies, M. N., Nguyen, C. T., Mathiesen, L., & Andersson, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26597000
Al-Jumaily, A., Araya, B. B., Malil, A., Oung, C., Joseph, F., & Joshi, T. (2026) · Cureus · doi:10.7759/cureus.105675
Tsubouchi, Y., Kataoka, T., Takase, R., Otsu, T., Hamanaka, R., Kataoka, M., & Kaku, N. (2026) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk11020159
Acido zoledronico: trattamento e prevenzione dell’osteoporosi
Minisola, S. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01826-x
Intarasattakul, N., Pongchaiyakul, C., Foocharoen, C., Suwannaroj, S., Nanagara, R., Thammaroj, P., & Mahakkanukrauh, A. (2026) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2026.101741
Preventing Hip (Proximal Femoral) Fractures: An Evidence-Based Review for Clinicians
Kawai, T., Okuzu, Y., Takaoka, Y., Natsume, D., & Matsuda, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166148 · Cited by 1
Paulo, S., Laranjo, M., Abrantes, A. M., Teixo, R. J., Fonseca, D. A., Mendes-Abreu, J., Figueiredo, J. P., Botelho, M. F., Ferreira, M. M., & Serra, A. (2026) · Pharmaceuticals · doi:10.3390/ph19081281
Yao, X., Chao, Y., Gu, X., Peng, J., Yuan, J., Shi, W., Zhang, F., & Bao, Q. (2026) · Orthopaedic Surgery · doi:10.1111/os.70429
Yen, H., Chiang, M.-H., Tsao, S.-L., Liu, J.-H., Tseng, T.-H., Lin, T.-C., Lee, C., Hung, C.-C., Huang, C., Fu, S., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.09.029 · Cited by 2
Beall, D. P., Beall, O. A., Webb, J. R., Johnson, J. C., & Mahmoud, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00002-8
Denosumab—efficacy, safety, persistence and sequential strategies—a systematic review
Laursen, N. A., Sølling, A. S., Harsløf, T., & Langdahl, B. L. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08237-6
Takigawa, M., Kotake, K., Tsuge, T., Saitsu, A., Isaji, Y., Kondo, S., Maruyama, T., & Yamamoto, N. (2026) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-026-01751-x
张树泉, Wang, Z., Zhou, R., Yu, W., Pang, Q., Jiajue, R., Cui, L., Liu, W., Jiang, Y., Li, M., et al. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08239-4
Elam, R. E., Schousboe, J. T., Finch, D. K., Huo, Z., Budde, E., Le, B. K., Dodson, T. B., Gerngross, P. J., Fink, H. A., Adler, R. A., et al. (2026) · Bone · doi:10.1016/j.bone.2026.118152
Metadata
- Authors
- Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G., & Eastell, R.
- Affiliations
- University of California, San Francisco (US)
- University of Auckland (NZ)
- KU Leuven (BE)
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- California Pacific Medical Center (US)
- University Hospital of Bern (CH)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Centro Médico TIEMPO, Buenos Aires, Argentina
- University of Sheffield (GB)
- Corresponding author
- Black, Dennis M
- ORCID
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-08
- Volume
- 27
- Issue
- 2
- Pages
- 243-254
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- PMC
- PMC3427916
- OpenAlex
- W2106406207
- Cited by
- 700
- References
- 40
- Citations by year
- 2026: 18 · 2025: 37 · 2024: 29 · 2023: 45 · 2022: 40 · 2021: 58 · 2020: 53 · 2019: 49 · 2018: 48 · 2017: 54 · 2016: 61 · 2015: 62 · 2014: 50 · 2013: 49 · 2012: 35
- FWCI
- 49.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- University of California, San Francisco
- Novartis Pharma
- National Center for Research Resources (UL1RR024153)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, osteoporosis, postmenopausal women, long-term treatment, bone mineral density, femoral neck, vertebral fractures, fracture risk, bone turnover markers, serum creatinine, atrial fibrillation, stroke, hypertension, bisphosphonates, adverse events
- MeSH terms
- Zoledronic Acid, Aged, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Osteoporosis, Peptide Fragments, Procollagen, Time Factors, Biomarkers, Bone Density, Incidence, Bone Remodeling, Treatment Outcome, Bone Density Conservation Agents, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
